• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Vaccines . The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

tetano

Editor, Senior Moderator
NPJ Vaccines


. 2022 Aug 30;7(1):103.
doi: 10.1038/s41541-022-00524-7.
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination


Johannes B Goll[SUP] 1 [/SUP], Aarti Jain[SUP] 2 [/SUP], Travis L Jensen[SUP] 1 [/SUP], Rafael Assis[SUP] 2 [/SUP], Rie Nakajima[SUP] 2 [/SUP], Algis Jasinskas[SUP] 2 [/SUP], Lynda Coughlan[SUP] 3 4 [/SUP], Sami R Cherikh[SUP] 1 [/SUP], Casey E Gelber[SUP] 1 [/SUP], S Khan[SUP] 2 [/SUP], D Huw Davies[SUP] 2 [/SUP], Philip Meade[SUP] 5 [/SUP], Daniel Stadlbauer[SUP] 5 6 [/SUP], Shirin Strohmeier[SUP] 5 [/SUP], Florian Krammer[SUP] 5 [/SUP], Wilbur H Chen[SUP] 3 [/SUP], Philip L Felgner[SUP] 7 [/SUP]



Affiliations

Abstract

Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.
 
Back
Top Bottom